Feb 14 (Reuters) - Johnson & Johnson JNJ.N said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.
In January, the company had paused the heart device, a pulsed field ablation system, citing an abundance of caution as it investigated four reported stroke events.
(Reporting by Mrinmay Dey in Bengaluru; Editing by William Mallard)
((mrinmay.dey@tr.com; +91 7362903319;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.